Negative life sciences sentiments recorded in September 2021

In the course of the monthly published FCF Life Sciences Venture Capital Monitor – Europe, the FCF Life Sciences team analyses the current sentiments in European life sciences venture capital funding per subsector.

In September 2021, a negative trend in venture capital financing activities was observed in all three subsectors Biotech, MedTech and HealthTech.

About FCF Life Sciences

FCF Life Sciences advises leading healthcare companies in Europe on financing transactions (equity, debt, and licensing) with regional and international investors. Our team consists of science-driven industry and finance experts with a strong track record in managing financing processes. We thrive to maximize the efficiency in the fundraising process and increase its closing probability.

Learn more about FCF Life Sciences, click here.

We closely track the activity in the financial markets and are passionate about capital markets research. Not every idea or research question make it into the final selection for our publications. However, we generate interesting information on financing trends in Life Sciences sector, which we would like to share in our blog.

To hear from us on the latest insights, please sign up here: